Articles tagged with Target Proteins
Researchers at The Scripps Research Institute found a protein, Protein M, that attaches to antibodies and prevents them from binding to their target, helping bacteria evade the immune response. This discovery could lead to new antibacterial therapies and tools for research and drug development.
Researchers at Stanford University developed a microarray to identify cytokines, chemokines, and other proteins targeted by SLE patients' autoantibodies. They found that patients with high levels of autoantibodies against B cell activating factor (BAFF) experienced more severe symptoms.
Researchers at the Buck Institute discovered a link between ApoE4 and SirT1, an anti-aging protein targeted by resveratrol. Increasing SirT1 may prevent Alzheimer's disease-related abnormalities in brain samples from patients with ApoE4 and AD.
Scientists at Scripps Research Institute have found a way to apply powerful new DNA-editing technology more broadly than ever before. They report their breakthrough in using designer TALE proteins that can target any DNA sequence, enabling precise gene manipulation for biotech and medical applications.
Researchers at the University of Texas at Dallas have discovered that Bacillus thuringiensis toxin selectively kills malaria-carrying mosquitoes by binding to the BT-R3 receptor. This finding opens up new avenues for designing customized proteins and peptides to combat mosquito-borne diseases, including malaria.
Researchers at UCSF have discovered a way to indirectly target myc-driven tumors using an experimental drug that targets the mTOR protein. Clinical trials for this new treatment approach may soon be available for patients with myc-driven cancers.
Scientists at Nanyang Technological University (NTU) have developed a new technique called Cellular Thermal Shift Assay (CETSA) that can accurately determine if a drug has reached its target protein in the human body. This breakthrough method will help reduce the costly and time-consuming trial-and-error process of drug development.
Researchers at Karolinska Institutet developed a breakthrough method called CETSA to measure drug molecules' binding to target proteins. This enables more efficient development of new drugs and potential improvement in cancer treatments.
Srikanth Singamaneni aims to create novel biosensors using self-assembled metal nanoparticles with artificial antibodies, improving specificity and sensitivity. He also plans to educate high-school science teachers and develop a nanotechnology kit for students.
Scientists have identified a new protective mechanism that could increase cell survival after stroke, highlighting the importance of SUMOylation in promoting nerve cell adaptation and survival. The discovery may lead to new therapies for stroke and other brain diseases.
A novel monoclonal antibody targeting SFRP2 has been shown to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. The antibody is the first therapeutic discovered that targets SFRP2, a protein linked to angiogenesis and cancer progression.
Researchers found that TRAP1 disrupts cancer cell metabolism, but inhibiting it could stimulate tumor progression. The protein regulates a metabolic 'switch' at the level of glucose digestion, which affects tumor stage and aggressiveness.
A new human monoclonal antibody, ESK1, has been developed to target proteins associated with many types of cancer, including leukemia and breast cancer. The antibody recognizes a protein called WT1, which is overexpressed in these cancers, and can kill cancer cells in preclinical research.
A study published in Nature describes how the CPEB1 protein 'takes the brakes off' the production of proteins associated with cell proliferation and tumor progression. The mechanism, discovered using Hodgkin lymphoma cells, has been proposed as a general regulatory system that enhances cancer spread.
Researchers have identified an Indian plant compound, gedunin, that attacks a co-chaperone of Hsp90 and leads to the inactivation of the Hsp90 machine, killing cancer cells. This finding may open new ways for targeting Hsp90 using established inhibitors.
CSHL scientists discovered a new protein, RNF20, essential for MLL-rearranged leukemia amplification. Suppressing RNF20 expression decreased leukemia cell proliferation and extended mouse lifespan.
Researchers identified the protein OTUD7B as TRAF3's protector, revealing its role in regulating a molecular pathway implicated in immune system-related diseases. OTUD7B suppressed non-canonical NF-kB signaling, leading to increased lymphoid cell growth and hyper-responsiveness to antigens.
A recent study by the Norwegian Institute of Public Health found no increased risk of fetal death associated with pandemic vaccination. The study analyzed data from pregnant women who received COVID-19 vaccines and compared them to those who did not receive vaccines.
Researchers at Georgetown University Medical Center discovered that BRCA1 targets cyclin B and Cdc25c proteins, regulating the G2/M checkpoint and halting cell division to allow DNA repair. This novel function explains BRCA1's role in maintaining genomic integrity and suppressing tumor growth.
Scientists have developed a way to create designer drugs that target multiple proteins simultaneously, potentially treating complex diseases like diabetes and schizophrenia. The new approach uses computational chemistry and experimental testing to validate drug compounds, showing promise for developing effective treatments.
Researchers found that targeting CD22 protein on lung cancer cells reduces tumor growth and metastasis in mouse models, leading to improved survival rates. The discovery may lead to the development of a novel therapy for non-small cell lung cancer.
Research found that protein import into chloroplasts is differentially regulated by age, with some proteins targeting young or old chloroplasts. The discovery sheds light on the complex regulation mechanisms governing protein transport and has implications for therapeutic applications.
Researchers at Dana-Farber Cancer Institute have successfully shut down breast cancer and leukemia in mice by targeting abnormal proteins that control cell growth. The study found that inhibiting cyclin D1 or D3 proteins halts cancer growth, while normal cells remain unaffected.
Researchers capture video footage of protein traffic inside a neuron using bioluminescent proteins, showing proteins are directed to compartments and then stopped. The new imaging technique provides insight into the brain's continuous renovation process.
Researchers cracked the molecular code for pentatricopeptide repeat (PPR) proteins, which recognize and bind specific RNA molecules. This discovery enables the potential for new treatments of genetic diseases and precise control over gene expression.
Researchers developed a targeted antisense approach to treat toxoplasmosis, reducing viable parasites by over 90% in mice. The therapy combines short nucleic acid strands with peptides to disrupt genetic signals, with potential applications in non-parasitic diseases.
Researchers at two structural genomics centers determined 1,000 protein structures from infectious disease organisms, providing crucial insights into the deadliest diseases. The knowledge gained will aid in developing new interventions and therapeutic agents for drug-resistant strains of TB, MRSA, and other pathogens.
Researchers found a common protein target among severe malaria strains, which can be blocked by antibodies to prevent rosette formation and severe illness. The discovery may inform the development of new treatments or vaccines against life-threatening cases of malaria.
A Purdue University biochemist is creating maps of all the potential routes for cancer cell formation, which could lead to more effective cancer drugs. By identifying kinases and their direct protein targets, researchers can tailor kinase-inhibiting drugs to block multiple pathways and make them more effective.
The new sensor uses nanometer-scale pores to selectively screen single molecules passing through a semiconductor membrane. The technology has the potential to detect and identify specific proteins in a single cell, with applications in medical research, pharmaceuticals, and fundamental biological studies.
Researchers found that blocking HSP90 activity renders protected proteins vulnerable to destruction, slowing the growth of MIF-expressing breast tumors. HSP90 inhibitors also showed promise in slowing leukemia cell growth driven by hyperactive JAK2 enzyme versions.
Researchers have identified Ric-8 as a chaperone that facilitates the transport of G proteins to the cell membrane. Without Ric-8, G proteins are destroyed and their biological processes are disrupted. Understanding the role of Ric-8 in G protein function may lead to more effective treatments for various diseases.
A new therapeutic target, EGFR, has been identified for treating Cushing disease. Clinical trials are necessary to investigate the effects of gefitinib in patients with this condition.
A novel antibacterial protein, Avidocin, demonstrates potential for preventing and treating E. coli O157:H7-induced diarrhea and intestinal inflammation in an animal study. The protein also carries fewer bacteria in the feces of infected animals, making it a promising alternative to conventional antibiotics.
Researchers have developed a new technique that can identify protein structures in just hours, revolutionizing the pharmaceutical industry. The enhanced NMR spectroscopy method using dynamic nuclear polarisation (DNP) enables significant structural data to be gained from small biological samples.
Biodesign researchers are developing a state-of-the-art pipeline to generate synthetic affinity reagents called 'DNA synbodies' to study protein function and disease. The goal is to create low-cost, high-quality reagents for the entire human proteome, revolutionizing molecular medicine.
Scientists have identified a key player in regulating fetal hemoglobin levels, paving the way for new treatments of sickle cell disease. Silencing a specific protein called BCL11A can reactivate fetal hemoglobin production, effectively reversing the condition in adult mice.
Researchers at Stanford University School of Medicine have identified EP4 as a potential new treatment target for stroke. A selective EP4 agonist administered after stroke reduced brain damage and long-term behavioral deficits in mice, suggesting its therapeutic potential.
Researchers predict numerous human proteins required by HIV to replicate, discovering potential new targets for controlling the spread of HIV. The study also identifies prognostic markers to determine pathological outcome and AIDS development.
Researchers used a new algorithm to predict human proteins that the HIV virus requires to replicate, offering potential new targets for controlling its spread. The study found many previously undiscovered proteins with high predictive value as prognostic markers.
Researchers identified FOBISIN, a compound that targets 14-3-3 proteins, which are dysregulated in multiple cancers. X-ray analysis showed FOBISIN permanently bonds to the protein when exposed to radiation, triggering potent anticancer activity
Scientists have successfully tuned bacteriophage endolysins to increase their effectiveness against C. difficile, a common cause of hospital-acquired infections. The study proposes using truncated versions of these natural antimicrobials as a new weapon in the battle against superbugs.
The foundation awarded individual grants to six new researchers and funded 18 collaborative grants, totaling over $3.1 million. The grants focus on reprogramming enzymes and genes into therapies to eradicate cancer stem cells.
Researchers developed a new technique to identify self-proteins targeted in autoimmune diseases. Using phage display technology, they created a proteome library to examine molecular details of immune responses.
Recent developments in protein kinase inhibitors include innovative drug development paradigms, improved inhibitor profiling, and expanded disease targets such as Alzheimer's disease. Researchers are focusing on inactive kinase states and using selectivity strategies to overcome obstacles in the field.
Researchers from top institutions receive awards for their work on ligand-binding assays, biotechnology innovations, and cancer treatment delivery. The American Association of Pharmaceutical Scientists recognizes excellence in these areas.
Researchers at JBEI have developed a technique called targeted proteomics that enables the rapid identification and quantification of specific proteins in cells or microbes. This technique can help identify bottlenecks in metabolic pathways, leading to improved efficiency and productivity in biofuel and therapeutic drug production.
A Purdue University biochemist has created a nanopolymer that can be coated with drugs and then removed to determine which proteins the drug has entered. This development may help reduce side effects associated with cancer drugs by allowing for more targeted drug delivery.
EMBL scientists first to visualize the structure of a ribosome-protein complex involved in carrying nascent proteins out of the cell. The discovery could increase understanding of illnesses such as cystic fibrosis and Parkinson's disease, where improper protein targeting leads to harmful accumulation inside cells.
Researchers found that human CML stem cells do not rely on BCR-ABL activity for survival, rendering traditional treatments ineffective. This breakthrough highlights the need for new therapeutic strategies to target these resilient cancer cells.
Researchers have discovered MIC-1 as a regulator of angiogenesis, finding that it is present in high levels in 67% of melanoma patients. Targeting this protein can prevent blood vessel formation and decrease tumor development by up to 300%. This could lead to new therapeutic strategies for treating melanoma.
Researchers at Boston Children's Hospital discovered that some HIV antibodies target the protein in its final form, making them ineffective. The team proposes designing immunogens to trap the protein in an intermediate state, preventing further structural rearrangements and blocking membrane fusion.
The Joint Center for Structural Genomics (JCSG), led by Ian A. Wilson, has made significant strides in high-throughput structural genomics, solving over 1,150 structures to date. The JCSG's pipeline has optimized every stage of the process, enabling large numbers of target proteins to be tackled simultaneously.
Researchers describe an indirect approach to reducing JAK2 activity by pharmacologically targeting HSP90. Inhibiting HSP90 normalized blood counts and improved survival in two mouse models of MPN, promoting JAK2 degradation in samples from patients with the disease.
A BU team led by Prof. Adrian Whitty aims to create 'drug-like' small molecule inhibitors targeting challenging protein-protein interactions with a $1.6M NIH grant. The goal is to develop new approaches for discovering inhibitors against intracellular proteins critical to human inflammatory diseases and cancers.
Two UNC School of Medicine faculty authored an editorial discussing the results of two clinical trials using Rituximab to treat small-vessel vasculitis, a rare autoimmune disease. The trials showed that Rituximab was effective in inducing remission compared to other treatments.
Researchers at Biogen Idec Inc. have found that targeting the TIM-1 protein may be effective in treating asthma. The study used a humanized mouse model to show that an antibody binding to a specific region of TIM-1 reduced inflammation and airway hyperresponsiveness.
Researchers identify two promising proteins, eIF5A and DHS, as potential targets for preventing diabetes. Blocking their actions significantly reduced the development of diabetes in mice, offering a new route for drug therapies.
A new study uses Nuclear Magnetic Resonance to predict how flexibility affects drug-like properties, enabling systematic manipulation of candidate drug molecules. The research aims to overcome issues of resistance, transportation, and oral bioavailability in drug design.
Researchers use powerful computers to identify molecular structures that have high potential as new medications by simultaneously targeting multiple hot spots on protein surfaces. This method has the potential to complement and increase efficiency of existing time-consuming methods.